Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

EGFRvIII Confers Sensitivity to Saracatinib in a STAT5-Dependent Manner in Glioblastoma

International Journal of Molecular Sciences(2024)10.3390/ijms25116279Source: DataRank Database

EGFRvIII Confers Sensitivity to Saracatinib in a STAT5-Dependent Manner in Glioblastoma is a research paper published in International Journal of Molecular Sciences (2024). On theSindex it has a DataRank of 0. It has been cited 7 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access7 citations

Download PDF

Cite:

Linked data & code

nct

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (4 grants)Impact (FWCI 1.24)OA: goldTopics (56)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (16)

Ryan Eghlimi ORCID,Angad Beniwal ORCID,Dustin Grief,David Nascari ORCID,Landon J. Inge ORCID

Live enrichment

PubMed:38892466 PMC:PMC11172708 OpenAlex:https://openalex.org/W4399389841

National Institutes of Health

Grant: R01 CA271431

National Institutes of Health

Grant: R56 NS120348

National Institutes of Health

Grant: 5R01CA271431-02

STAT5/OLIG2 regulation of GBM therapeutic resistance and recurrence - Resubmit 3.22

National Institutes of Health

Grant: 1R56NS120348-01

Enhancing Treatment Response by Leveraging STAT5-OLIG2 signaling in GBM

FWCI

1.24

Citation Percentile

0.8%

Citation Trend

2025

2026

goldLicense: cc-by

journalhttps://www.mdpi.com/1422-0067/25/11/6279/pdf?version=1717681528

publisherhttps://www.mdpi.com/1422-0067/25/11/6279/pdf?version=1717681528

publisherhttps://www.mdpi.com/1422-0067/25/11/6279/pdf

journalhttps://doi.org/10.3390/ijms25116279

repositoryhttps://pubmed.ncbi.nlm.nih.gov/38892466

Fields of Study

Cytokine Signaling Pathways and InteractionsLung Cancer Treatments and MutationsCancer Mechanisms and Therapy0301 basic medicine03 medical and health sciences0303 health sciences

MeSH Terms

TemozolomideAnimalsBrain NeoplasmsGlioblastomaHumansPhosphorylationQuinazolinesSignal TransductionApoptosissrc-Family KinasesXenograft Model Antitumor AssaysTumor Suppressor ProteinsCell Line, TumorCell ProliferationSTAT5 Transcription FactorMiceBenzodioxolesErbB Receptors

Keywords

STAT5Cancer researchTemozolomidePhosphorylationSignal transductionMedicineIn vivoHEK 293 cellsCell growthBiologyCell cultureGlioblastomaCell biologyGeneticsReceptor tyrosine kinaseCell signalingPrecision OncologyApoptosisArticleMiceCell Line, TumorSTAT5 Transcription FactorHumansAnimalsBenzodioxolesCell ProliferationBrain NeoplasmsTumor Suppressor ProteinsXenograft Model Antitumor AssaysErbB Receptorssrc-Family KinasesQuinazolines

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being